By Fineline Cube 
US-based Viz.ai this week announced a multi-year partnership with France-based Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease (COPD). This collaboration aims to enhance the detection and management of high-risk COPD patients through advanced technology.
Viz COPD Module
Viz.ai, supported by Sanofi and Regeneron, will investigate the use of the Viz COPD module, a care acceleration solution that leverages electronic health record (EHR) data and artificial intelligence (AI) to advance the detection and management of high-risk COPD patients. The Viz COPD module is based on Viz.ai’s existing presence in over 1700 hospitals and healthcare systems, as well as support from over 60,000 healthcare providers on the platform.-Fineline Info & Tech